Medicus Pharma (NASDAQ:MDCX) Stock Price Down 5.2% – Should You Sell?

Shares of Medicus Pharma Ltd (NASDAQ:MDCX) dropped 5.2% during trading on Monday . The stock traded as low as $0.32 and last traded at $0.32. Approximately 1,567,068 shares changed hands during trading, a decline of 31% from the average daily volume of 2,280,738 shares. The stock had previously closed at $0.3377.

Wall Street Analyst Weigh In

MDCX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. Roth Mkm assumed coverage on Medicus Pharma in a research report on Tuesday, April 21st. They issued a “buy” rating on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.00.

Medicus Pharma Stock Performance

The company has a 50 day moving average of $0.34 and a 200-day moving average of $0.93. The stock has a market cap of $18.13 million, a price-to-earnings ratio of -0.12 and a beta of 0.12.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). On average, research analysts anticipate that Medicus Pharma Ltd will post -0.51 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Medicus Pharma in the second quarter valued at approximately $41,000. HRT Financial LP acquired a new stake in Medicus Pharma during the 4th quarter worth approximately $42,000. Osaic Holdings Inc. lifted its holdings in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after buying an additional 9,000 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Medicus Pharma by 161.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after buying an additional 17,611 shares during the period. Finally, May Hill Capital LLC grew its stake in shares of Medicus Pharma by 100.0% in the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock worth $55,000 after acquiring an additional 17,811 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.